David Guyer

Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI.

SV Health Investors LLC is a Venture Capital firm, a subsidiary of SV Health Investors LLP founded in 2006. SV Health Investors LLC is headquartered in Boston.

Optos Plc manufactures and markets retinal imaging devices. Its products include ultra-widefield imaging, visual acuity, perimetry, and laser treatment products. The company was founded by Douglas Crombie Anderson in 1992 and is headquartered in Dunfermline, the United Kingdom.

Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

AlloCure, Inc. develops cell therapies for the treatment of kidney diseases. It engages in developing allogeneic mesenchymal stem cell therapy for acute kidney injury. The company was founded in 2008 and is headquartered in Burlington, MA.

Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada.

Carter BloodCare engages in the provision of blood components and transfusion services for North, Central and East Texas. It offers collection, testing, and distribution of blood on a local level. It also provides technical support services and educational programs to employees of area healthcare organizations. The company was founded on January 1, 1998 and is headquartered in Bedford, TX.

PanOptica, Inc. operates as a biopharmaceutical company that provides ophthalmology drugs for treatment of eye diseases. The company was founded by Paul G. Chaney and Martin B. Wax in March 2009 and is headquartered in Bernardsville, NJ.

Imagen Biotech, Inc. develops therapeutics for sight-threatening diseases. The firm specializes in personalized chemotherapy, medicine, high content screening, cell biology and contract research. The company was founded by David R. Guyer and Matthew Feinsod in 2011 and is headquartered in New York, NY.

iSTAR Medical SA develops innovative ophthalmic implants. Its products include MINIject, STARflo and STAR Material. The company was founded by Michel Alvarez in 2011 and is headquartered in Wavre, Belgium.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

Invectys, Inc. is a biopharmaceutical company that focuses on developing immunotherapy treatments for cancer. The private company is based in Houston, TX. Invectys was founded in 2010 and Praveen Tyle has been the CEO of the company since 2021.

Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023.

Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021.